Maravai Lifesciences Holdings Stock Net Asset
| MRVI Stock | USD 5.92 0.30 5.34% |
Maravai Lifesciences Holdings fundamentals help investors to digest information that contributes to Maravai Lifesciences' financial success or failures. It also enables traders to predict the movement of Maravai Stock. The fundamental analysis module provides a way to measure Maravai Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Maravai Lifesciences stock.
Maravai | Net Asset |
Maravai Lifesciences Holdings Company Net Asset Analysis
Maravai Lifesciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Maravai Lifesciences Net Asset | 1.49 B |
Most of Maravai Lifesciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Maravai Lifesciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Maravai Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Maravai Lifesciences is extremely important. It helps to project a fair market value of Maravai Stock properly, considering its historical fundamentals such as Net Asset. Since Maravai Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Maravai Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Maravai Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Maravai Total Assets
Total Assets |
|
Based on the recorded statements, Maravai Lifesciences Holdings has a Net Asset of 1.49 B. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Maravai Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Maravai Lifesciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Maravai Lifesciences could also be used in its relative valuation, which is a method of valuing Maravai Lifesciences by comparing valuation metrics of similar companies.Maravai Lifesciences is currently under evaluation in net asset category among its peers.
Maravai Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Maravai Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Maravai Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Maravai Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in Maravai Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Maravai Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Maravai Lifesciences' value.| Shares | Ameriprise Financial Inc | 2024-06-30 | 3 M | Jennison Associates Llc | 2024-09-30 | 3 M | State Street Corp | 2024-06-30 | 2.8 M | Geode Capital Management, Llc | 2024-09-30 | 2.8 M | Point72 (difc) Ltd | 2024-09-30 | 2.7 M | Fmr Inc | 2024-09-30 | 2.5 M | Glenmede Trust Co Na | 2024-09-30 | 2.2 M | Alyeska Investment Group, L.p. | 2024-09-30 | 2.2 M | Bamco Inc | 2024-09-30 | 2.1 M | Gtcr Llc | 2024-09-30 | 20.2 M | 12 West Capital Management Lp | 2024-09-30 | 14 M |
Maravai Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.81) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 822.63 M | ||||
| Shares Outstanding | 141.84 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 98.70 % | ||||
| Number Of Shares Shorted | 6.96 M | ||||
| Price To Earning | 7.79 X | ||||
| Price To Book | 2.43 X | ||||
| Price To Sales | 5.40 X | ||||
| Revenue | 288.94 M | ||||
| Gross Profit | 714.04 M | ||||
| EBITDA | 712.41 M | ||||
| Net Income | (119.03 M) | ||||
| Cash And Equivalents | 617.45 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 610.97 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 7.22 X | ||||
| Book Value Per Share | 2.44 X | ||||
| Cash Flow From Operations | 126.22 M | ||||
| Short Ratio | 3.10 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.22) X | ||||
| Target Price | 9.73 | ||||
| Number Of Employees | 580 | ||||
| Beta | 0.024 | ||||
| Market Capitalization | 1.49 B | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 285.74 M | ||||
| Working Capital | 612.44 M | ||||
| Net Asset | 1.49 B |
About Maravai Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Maravai Lifesciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maravai Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maravai Lifesciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:Check out Maravai Lifesciences Piotroski F Score and Maravai Lifesciences Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.67) | Revenue Per Share 2.044 | Quarterly Revenue Growth (0.03) | Return On Assets (0.02) |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.